4D pharma plc (AIM: DDDD) and The University of Texas MD Anderson Cancer Center announced on 1/7/19 a strategic collaboration to evaluate 4D’s Live Biotherapeutic oncology pipeline across a range of cancer settings.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,